Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolff, A. C.
Right arrow Articles by Press, M. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wolff, A. C.
Right arrow Articles by Press, M. F.

HER2 as a Predictive Marker: Why Bother Testing?

Antonio C. Wolff, MD, FACP, Soonmyung Paik, MD, and Michael F. Press, MD, PhD

From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; NSABP Division of Pathology, Pittsburgh, Pennsylvania; and the University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Antonio C. Wolff, MD, Assistant Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 189, Baltimore, MD 21231; e-mail: awolff{at}jhmi.edu

Overview: This review will list current approaches to HER2 testing, describe current controversies in predictive markers for HER2-directed therapy, and describe recent data on improved approaches to HER2 testing.